Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: Results of a phase I/II trial

British Journal of Cancer

Volumn 99, Issue 7, 2008, Pages 1020-1026

  Lorenzen, S ^a   Brucher B ^b   Zimmermann, F ^a   Geinitz, H ^a   Riera, J ^c   Schuster, T ^d   Roethling, N ^a   Hofler H ^e   Ott, K ^f   Peschel, C ^a   Siewert, J R ^g   Molls, M ^a   Lordick, F ^f  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

5 fluorouracil; Chemoradiotherapy; Neoadjuvant; Oesophageal carcinoma; Oxaliplatin; Response

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG INFUSION; DYSESTHESIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LETHARGY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TUMOR CELL; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 53049091239     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604659     Document Type: Article

References (41)

1. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA (2001) A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92: 279-286
2. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of combined radiochemotherapy vs radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15: 277-284
3. Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S (2005) A phase I-II study of weekly oxaliplatin 5-fluorouracil continuous infusion and pre-operative radiotherapy in locally advanced rectal cancer. Ann Oncol 16: 1140-1146
4. Bartels H, Stein HJ, Siewert JR (1998) Pre-operative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 85: 840-844
5. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE (1996) Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 14: 156-163
6. Becker K, Mueller JD, Schumacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98: 1521-1530
7. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168
8. Blackstock AW, Hess S, Chaney S, Tepper JE (1999) Oxaliplatin: in vitro evidence of its radiation sensitizing activity. Pre-clinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45(Suppl 1): 253-254; (Abstract 202)
9. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Radiochemotherapy followed by surgery compared with surgery alone in localized squamous cell cancer of the esophagus. N Engl J Med 337: 161-167
10. Brown LD, Cai TT, DasGupta A (2001) Interval estimation for a binomial proportion. Stat Sci 16: 101-117
11. Brücher BLDM, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinoma. Cancer 106: 2119-2127
12. Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi DT (2002) Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52: 1092-1098
13. Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Adenis A (2007) Definitive chemo-radiotherapy (CRT) with FOLFOX 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study. J Clin Oncol 25(Suppl 18): 4532(Abstract)
14. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, for the Australasian Gastro-Intestinal Trials Group (2007) Survival benefits from neoadjuvant radiochemotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234
15. Gehan EA (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353
16. Grothey A, Deschler M, Kroening H, Ridwelski K, Reichard P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HF (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA+oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21: 129a (abstract 512)
17. Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA (2000) Phase II evaluation of pre-operative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18: 868-876
18. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598
19. Hofstetter W, Swisher S, Correa A, Hess K, Putnam Jr JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA (2002) Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-385
20. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG (2007) Long-term results of RTOG Trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25: 3719-3725
21. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20: 2844-2850
22. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C (2005) Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93: 190-194
23. Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: The RadiOxCape Study. Ann Oncol 16: 1898-1905
24. Magne N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, Lagrange JL, Milano G (2003) Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of the p53 status. Oncology 64: 280-287
25. Mariette C, Finzi L, Fabre S, Balon JM, Van Seuningen I, Triboulet JP (2003) Factors predictive of complete resection of operable esophageal cancer. A prospective study. Ann Thorac Surg 75: 1720-1726
26. McMullen KP, Blackstock AW (2002) Chemoradiation with novel agents for rectal cancer. Clin Colorectal Cancer 2: 24-30
27. Meluch A, Greco F, Gray J, Thomas M, Sutton VM, Davis JL, Kalman LA, Shaffer DW, Yost K, Rinaldi DA, Hainsworth JD (2003) Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II Trial. Cancer J 9: 251-260
28. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, AIO Colorectal Study Group (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223
29. Rice WR (1988) A new probability model for determining exact P-values for 2x2 contingency tables when comparing binomial proportions. Biometrics 44: 1-14
30. Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25: 110-117
31. Rutten H, Sebag-Montefiori D, Glynne-Jones R, Rullier E, Peeters M, Brown G, Van Cutsem E, Ricci S, Van de Velde CJ, Quirke P (2006) Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol 24: 153s (suppl; abstract 3528)
32. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343 -346
33. Siewert JR, Hoelscher AH, Roder ID, Bartels H (1998) En-bloc esophagectomy in esophageal cancer. Langenbecks Arch Chir 373: 367-376
34. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317
35. Stahl M, Wilke H, Fink U, Stuschke M, Walz MK, Siewert JR, Molls M, Fett W, Makoski HB, Breuer N, Schmidt U, Niebel W, Sack H, Eigler FW, Seeber S (1996) Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol 14: 829-837
36. Steinau HU, Biemer E, Bader M, Holscher M, Siewert JR (1988) Reconstruction of the Cervical Esophagus by Microsurgical Transfer of Intestinal Segment. Springer: New York
37. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA (2005) Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following pre-operative chemoradiation (CRT). Ann Surg 241: 810-820
38. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26(7): 1086-1092
39. van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA (2008) A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol 15: 88-95
40. Van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, ten Kate FJ, Obertop H (2001) Hospital volume and hospital mortality for esophagectomy. Cancer 91: 1574-1578
41. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP (1996) A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467